Patents by Inventor Mark Holterman

Mark Holterman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutant human CD80 and compositions for and methods of making and using the same
    Patent number: 8202847
    Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: June 19, 2012
    Assignees: The Trustees of the University of Pennsylvania, Valorisation-Recherche, Societe En Commandite
    Inventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
  • MUTANT HUMAN CD80 AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20110002956
    Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
    Type: Application
    Filed: November 10, 2008
    Publication date: January 6, 2011
    Inventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
  • Nucleic acids encoding mutant human CD80 and compositions comprising the same
    Patent number: 7446189
    Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: November 4, 2008
    Assignees: Institut de Recherches Cliniques de Montreal, The Trustees of the University of Pennsylvania, Valorisation-Recherche, Societe en Commandite
    Inventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
  • USES OF BISPECIFIC ANTIBODY COATED DENDRITIC CELLS PULSED WITH ANTIGENS AND GM-CSF IN IMMUNE REGULATION
    Publication number: 20070184031
    Abstract: GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
    Type: Application
    Filed: November 16, 2006
    Publication date: August 9, 2007
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Bellur Prabhakar, Mark Holterman, Chenthamarakshan Vasu
  • Per-6-substituted-per-6-deoxy-cyclodextrins, and use of the same to inhibit soluble beta-amyloid-peptide derived oligomers and to treat alzheimer's and related diseases
    Publication number: 20050059634
    Abstract: Per-6-substituted-per-6-deoxy-cyclodextrins and compositions containing the same are disclosed. The compounds and compositions inhibit the formation and/or activity of soluble ?-amyloid-peptide derived oligomers, and can be used to treat diseases and conditions wherein such inhibition is beneficial, for example, Alzheimer's disease.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 17, 2005
    Inventors: Duane Venton, William Klein, Gregory Thatcher, Lei Chang, Rong Liu, Zhiqiang Wang, Mark Holterman